The NCI selected Open Biosystems to verify the effectiveness of lentiviral microRNA-adapted shRNAmir technology in 135 specifically targeted cancer genes. shRNAmir technology is an effective technique to simplify the discovery and validation of tumor suppressor functions.
With NCI funding, Open Biosystems will functionally validate the knock-down efficiency of shRNAmir lentiviral constructs when targeting specific cancer genes.
Open Biosystems believes that this study will provide researchers with a validated set of cancer gene targeting reagents and data. In the first quarter of 2007, researchers will be able to access cancer-specific shRNAmir reagents through Open Biosystems and the corresponding knock-down data through the NCI. This in turn can be used to better identify and study the specific genes involved in the development of cancer.